Production Methods for a Mesenchymal Stem Cell Therapeutic as a Medical Defense Countermeasure
Abstract
The application of cellular therapies to treat battlefield injuries offers a novel and promising approach to address longstanding challenges in the repair of tissue damage with regard to both structural and functional improvement. The results of currently published investigations describing mesenchymal stem cell (MSC) efficacy in a variety of injury models demonstrate the unique qualities of this reparative cell population to adapt to the requirements of the damaged tissue in which the cells integrate. MSC therapy represents a single medical intervention that can simultaneously provide a broad range of therapeutic efficacy, with local activity, at multiple tissue and organ sites. The data presented in this report demonstrate that MSCs can be routinely isolated from adult bone marrow and expanded in cell culture to consistently and reliably produce pharmaceutical quantities of therapeutic product. Characterization of stem cell properties of culture-expanded MSCs is shown by in vitro differentiation to form mature cell types. The production methodology described will provide the means for producing test material for use in evaluating MSC therapy as a candidate treatment modality for injuries of concern to medical defense.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2012
- Accession Number
- ADA558893
Entities
People
- Christopher M. Bowens
- Erik B. Eaton Jr.
- John G. Lehman Iii
- Timothy R. Varney
Organizations
- United States Army Medical Research Institute of Chemical Defense